Welcome to our dedicated page for Sharps Technology SEC filings (Ticker: STSSW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Sharps Technology’s disclosures can feel like drawing blood from a stone—hundreds of pages on syringe patents, sterilization protocols, and global manufacturing plans. Yet those details move the share price. Our platform turns that complexity into clarity.
What you’ll find here:
- Sharps Technology insider trading Form 4 transactions linked to executive stock activity
- Sharps Technology quarterly earnings report 10-Q filing with AI commentary on production costs
- Sharps Technology Form 4 insider transactions real-time alerts—no EDGAR digging required
- Sharps Technology SEC filings explained simply through AI-powered plain-language summaries
- Sharps Technology earnings report filing analysis that highlights syringe demand trends
- understanding Sharps Technology SEC documents with AI for faster due diligence
- Sharps Technology executive stock transactions Form 4 pattern recognition tools
- Sharps Technology annual report 10-K simplified—patents, plant capacity, risk factors
- Sharps Technology proxy statement executive compensation unpacked line by line
- Sharps Technology 8-K material events explained within minutes of posting
Our AI scans every newly posted 10-K, 10-Q, 8-K or S-1 and delivers real-time highlights: which SecureGard units shipped, how Hungarian output ramped, and whether management granted itself fresh options. Form 4 alerts surface insider moves before markets react, while keyword search points you straight to waste-reduction metrics buried deep in the footnotes. Want to compare quarter-over-quarter syringe margins? It’s pre-calculated. Need the exact wording on re-use prevention standards? One click opens the section in context.
Stop wading through technical jargon. Stock Titan’s AI-powered summaries, expert annotations, and real-time updates make Sharps Technology filings actionable, letting you focus on decisions—not document hunts.
Sharps Technology Inc. reported a material event describing issuance mechanics for warrants tied to a transaction: Strategic Advisor Warrants equal to 10% of the combined Cash Shares and Pre-Funded Warrant Shares, and upon exercise of each Stapled Warrant the Strategic Advisor receives additional warrants equal to 10% of the Stapled Warrant Shares exercised. The Strategic Advisor Warrants allow purchase of Common Stock (referred to as Strategic Advisor Warrant Shares). The filing discloses that Sol Markets, which is controlled by James Zhang, is related by family to the company through Alice Zhang, the company’s Chief Investment Officer and a Director. A company website link is provided.
Sharps Technology Inc. (STSS/STSSW) director Timothy James Ruemler reported four separate sales of company common stock on 08/27/2025, each for 5,000 shares at prices of $16.575, $16.54, $17.0922 and $16.75. After these transactions his beneficial ownership fell from 35,218 shares to 20,218 shares as shown on the form. The filing includes an explanatory note stating the shares were sold inadvertently and that Mr. Ruemler has tendered $90,600 to the company to cover short-swing profits. The Form 4 is signed and dated 08/28/2025.
Timothy James Ruemler, a director of Sharps Technology Inc., reported multiple dispositions of Common Stock on 08/25/2025 at prices ranging from $9.60 to $12.50, after which he beneficially owns 40,218 shares. The Form 4 also discloses a grant of an option under the company's 2025 Equity Incentive Plan dated 08/22/2025 to purchase 80,000 shares at an exercise price of $6.41. The option will become 100% vested and exercisable on May 22, 2026, and the option covers 80,000 underlying common shares.
Jason L. Monroe, a director of Sharps Technology Inc. (STSS), was granted an option to purchase 80,000 shares on 08/22/2025 with an exercise price of $6.41 per share. The option was granted under the company’s 2025 Equity Incentive Plan and will become 100% vested and exercisable on May 22, 2026. The Form 4 was signed by Mr. Monroe on 08/26/2025.
Andrew R. Crescenzo, who serves as Chief Financial Officer and a director of Sharps Technology Inc., was granted an option to purchase 40,000 shares on 08/22/2025 at an exercise price of $6.41 per share under the company's 2025 Equity Incentive Plan. The option is shown as directly beneficially owned for 40,000 shares following the grant and will become 100% vested and exercisable on May 22, 2026. The Form 4 was signed by Mr. Crescenzo on 08/26/2025. The filing lists the issuer as Sharps Technology Inc. (STSS).
Robert M. Hayes, a director of Sharps Technology Inc. (ticker shown as STSS), reported a securities transaction on a Form 4. The filing records an option (right to buy) for 100,000 shares with a price of $6.41. The transaction line shows the option entry dated 08/22/2025 and indicates the shares were acquired (code A) and are held directly. The filing notes the grant was made under the Company’s 2025 Equity Incentive Plan and that the option will be 100% vested as of the issuance date. The form includes an earliest-transaction date of 12/04/2024 and a signature dated 08/26/2025.
The reporting person, Soren Bo Christiansen, a director of Sharps Technology Inc. (STSS), was granted an option to purchase 80,000 shares on 08/22/2025 at an exercise price of $6.41 per share under the company's 2025 Equity Incentive Plan. The option will become 100% vested and exercisable on May 22, 2026. Following the grant the reporting person beneficially owns 80,000 shares/options as reported.
Paul K. Danner, a director of Sharps Technology Inc. (STSS), was granted options to purchase 400,000 shares at an exercise price of $6.41 per share. The grant was reported with a transaction date of 08/22/2025 and the option is scheduled to become 100% vested and exercisable on May 22, 2026. Following the reported transaction, Mr. Danner beneficially owns 400,000 shares subject to the option on a direct basis. The grant was made pursuant to the company's 2025 Equity Incentive Plan.